

GLAXOSMITHKLINE PLC  
Form 6-K  
August 06, 2009

**FORM 6-K**

**SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549**

**Report of Foreign Issuer**

**Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934**

For period ending August 2009

**GlaxoSmithKline plc**  
(Name of registrant)

**980 Great West Road, Brentford, Middlesex, TW8 9GS**  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the

information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No x

--

### Notifiable Share Interest in Vernalis plc ("Vernalis")

GlaxoSmithKline plc ("GSK") announces that on 5 August 2009, SmithKline Beecham Corporation, a wholly owned subsidiary of GSK, agreed to subscribe for 2,040,542 ordinary shares in Vernalis (representing 3.39% of the enlarged share capital of Vernalis) for an aggregate subscription price of £1.77 million (\$3 million). Vernalis plc is a development stage pharmaceutical company whose shares are traded on the London Stock Exchange..

The subscription is being made in connection with a collaboration, option and license agreement reached between the two companies, relating to a Vernalis research programme in oncology. An up-front payment in cash of \$3 million was also made to Vernalis plc on signing of the agreement.

S M Bicknell

Company Secretary

5 August 2009

Enquiries:

|                     |                    |                 |
|---------------------|--------------------|-----------------|
| UK Media enquiries: | Philip Thomson     | (020) 8047 5502 |
|                     | David Outhwaite    | (020) 8047 5502 |
|                     | Stephen Rea        | (020) 8047 5502 |
|                     | Alexandra Harrison | (020) 8047 5502 |

|                     |                 |                |
|---------------------|-----------------|----------------|
| US Media enquiries: | Nancy Pekarek   | (919) 483 2839 |
|                     | Mary Anne Rhyne | (919) 483 2839 |
|                     | Kevin Colgan    | (919) 483 2839 |
|                     | Lisa Behrens    | (919) 483 2839 |

|                                      |                |                 |
|--------------------------------------|----------------|-----------------|
| European Analyst/Investor enquiries: | David Mawdsley | (020) 8047 5564 |
|                                      | Sally Ferguson | (020) 8047 5543 |
|                                      | Gary Davies    | (020) 8047 5503 |

|                                 |                 |                |
|---------------------------------|-----------------|----------------|
| US Analyst/ Investor enquiries: | Tom Curry       | (215) 751 5419 |
|                                 | Jen Hill Baxter | (215) 751 7002 |

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

**GlaxoSmithKline plc**  
(Registrant)

Date: August 6 2009

By: VICTORIA WHYTE

-----

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc